Wellspect
Wellspect, a leading name in the medical technology industry, is headquartered in Sweden (SE) and operates extensively across Europe and North America. Founded in 2014, the company has quickly established itself as a pioneer in innovative healthcare solutions, particularly in the fields of urology and continence care. Wellspect is renowned for its core products, including the LoFric range of intermittent catheters, which are distinguished by their unique hydrophilic coating that enhances comfort and reduces the risk of urinary tract infections. The company’s commitment to quality and patient-centric design has positioned it as a trusted partner in healthcare, achieving notable recognition for its contributions to improving patient outcomes. With a focus on research and development, Wellspect continues to lead the way in advancing medical technologies that empower individuals to manage their health with confidence.
DitchCarbon Score
How does Wellspect's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Wellspect's score of 45 is higher than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Wellspect's reported carbon emissions
Wellspect AB, headquartered in Sweden, has set ambitious climate commitments aimed at significantly reducing its greenhouse gas (GHG) emissions. Although specific emissions data for the most recent year is not available, the company has established a comprehensive framework for its climate initiatives. Wellspect has committed to achieving net-zero GHG emissions across its entire value chain by 2045. This long-term goal includes substantial near-term targets: a reduction of absolute Scope 1 and 2 emissions by 80% by 2030, based on a 2021 baseline. Additionally, the company aims to cut its absolute Scope 3 emissions—covering upstream transportation, waste generated in operations, and upstream leased assets—by 42% within the same timeframe. For the long term, Wellspect plans to reduce its absolute Scope 1 and 2 emissions by 95% and Scope 3 emissions by 90% by 2045. Furthermore, the company is committed to ensuring that 74.9% of its suppliers, measured by emissions from purchased goods and services, capital goods, and upstream transportation, will have science-based targets by 2026. These targets align with the Science Based Targets initiative (SBTi) and reflect Wellspect's commitment to contributing to global efforts to limit temperature rise to 1.5°C. The company’s proactive approach underscores its dedication to sustainability and responsible environmental stewardship in the healthcare equipment and supplies sector.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Wellspect is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
